Investigation of Leukocyte Trafficking Into Skin Blisters During Cardiopulmonary Bypass
Completed
British Heart Foundation
N/A
2003-01-01
The purpose of this study was to see if the heart-lung machine involved in cardiac surgery
increases the movement of activated white blood cells from the bloodstream into the patient's
tissues and also to see if aprotinin usage during surgery reduces this effect.
Investigation of Leukocyte Trafficking Into Skin Blisters During Cardiopulmonary Bypass
Completed
Imperial College London
N/A
2003-01-01
The purpose of this study was to see if the heart-lung machine involved in cardiac surgery
increases the movement of activated white blood cells from the bloodstream into the patient's
tissues and also to see if aprotinin usage during surgery reduces this effect.
"Salvage Use" of Recombinant Factor VIIa After Inadequate Haemostasis in Complex Cardiac Surgery
Unknown status
Austin Health
Phase 3
2005-06-01
Aims and Hypotheses:
This randomised placebo controlled study will test the hypothesis that Recombinant Activated
Factor VII (rVIIa) will improve haemostasis after an inadequate response to conventional
therapy in complex cardiac surgery.
Major bleeding is still of concern in complex cardiac surgery. It has been shown to be
associated with poorer patient outcome and results in the consumption of resources (hospital
costs, manpower and blood bank reserves). This study has the potential to provide evidence
that rVIIa can reduce transfusion requirements and improve patient outcome in a problematic
aspect of complicated cardiac surgery.
The objective is to conduct a multi-centre randomised placebo controlled study that has been
designed to scientifically evaluate the treatment of post bypass coagulopathy in the
association with complex cardiac surgery. The trial design is based on clinical practice that
has evolved over 2 years at the Austin Hospital during which 38 patients have received open
label administration of rVIIa. There is currently no published RCT in this area and there is
no TGA approval for the use of rVIIa for this indication.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.